Welcome to our dedicated page for Harte Hanks news (Ticker: HHS), a resource for investors and traders seeking the latest updates and insights on Harte Hanks stock.
Harte Hanks, Inc. (NASDAQ:HHS) is a global customer experience and data-driven marketing company whose news flow centers on financial performance, strategic partnerships, technology initiatives and transformation progress. The company regularly issues earnings releases detailing results for its Customer Care, Fulfillment & Logistics and Marketing Services segments, along with commentary on cost structure, EBITDA trends and balance sheet strength.
Investors following HHS news will see quarterly and full-year results, updates on its multi-year transformation program Project Elevate, and disclosures about leadership changes such as the appointment of a new President to oversee business segments and M&A initiatives. Harte Hanks also reports on material financing developments, including amendments to its asset-based revolving credit facility with Texas Capital Bank that extend maturities and add borrowing flexibility.
Operational and commercial updates are another key theme. Recent announcements include the opening of a dedicated Customer Care center in Greenville, South Carolina in partnership with Samsung Electronics America, and exclusive rights to license ADS Data Direct’s Medical Ailment Database to support compliant, high-precision healthcare marketing. The company also highlights collaborations with technology providers, such as its work with Reddy to apply AI-driven coaching and training within global contact center operations.
This news page aggregates these earnings releases, 8-K-linked announcements and corporate updates so readers can track how Harte Hanks executes its customer experience strategy, manages its capital resources and expands relationships with major brands across healthcare, technology, consumer, financial services and other sectors.
Harte Hanks (NASDAQ: HHS) has appointed Don Aicklen as the new Senior Vice President of Sales and Marketing, returning to the company with extensive sales experience. Aicklen previously led Harte Hanks' national sales organization, contributing to significant growth, particularly in automotive and consumer durables. His past leadership at KBM Group and startups in marketing services also highlights his expertise. CEO Brian Linscott praised Aicklen's talent and strategic vision to drive growth initiatives in 2022 and beyond.
Harte Hanks, Inc. (HHS) announced a new $25 million revolving line of credit with Texas Capital Bank on Dec. 21, 2021. This credit facility aims to enhance the company's strategic position and financial flexibility, allowing for working capital, debt repayment, and investment in client offerings. CEO Brian Linscott highlighted the facility's importance for ensuring financial stability and eliminating the need for third-party guarantees, showcasing the success of their turnaround plan.
Harte Hanks, Inc. (OTCQX: HRTH) has announced its approval for listing on the Nasdaq, effective December 1, 2021, where it will trade under the symbol 'HHS'. The company has met stringent financial and corporate governance requirements. This uplisting is viewed as a significant milestone that is expected to enhance liquidity and investor access. Chairman Jack Griffin emphasized the return to a national exchange as a major progress indicator, while CEO Brian Linscott highlighted the potential to expand the institutional shareholder base and increase long-term shareholder value.
Harte Hanks (NYSE: HHS) was notified by the NYSE on July 9, 2020, about the commencement of delisting proceedings due to non-compliance with listing standards, specifically failing to maintain $50 million in stockholders' equity or market capitalization. The company plans to transition to the OTCQX Best Market, where it will trade under the symbol "HRTE." Despite the delisting, Harte Hanks asserts that its business operations will remain unaffected. The NYSE will inform about the suspension date after the review period.
Harte Hanks (NYSE: HHS) has been chosen by Flagship Biosciences to implement a strategic marketing campaign aimed at enhancing customer acquisition. This initiative will encompass a targeted, multi-channel approach, integrating email, digital advertising, and content creation to engage critical decision-makers in the biotechnology sector. The campaign's objective is to showcase Flagship's capabilities in accelerating drug development and improving patient outcomes, leveraging Harte Hanks' expertise in behavioral marketing.
Harte Hanks (NYSE: HHS) announced the upcoming release of its financial results for Q1 2020, which ended on March 31, 2020. The results will be made public on May 14, 2020, after market close. A conference call to discuss these results is scheduled for the same day at 4:30 p.m. ET. Interested parties can join the call by dialing (877) 300-8521 or (412) 317-6026, using conference ID 10144089. The call will also be available via live webcast on the company's website, along with a replay for 90 days following the event.